Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

BioPlus Specialty Pharmacy Unveils "Hope Delivered in 24 Hours" for Oncology Patients
  • USA - English

Nationwide specialty pharmacy commits to accelerated delivery of generic oncology medication, capecitabine; brings hope and faster time to treatment for patients, including those with metastatic colon or breast cancers.


News provided by

BioPlus Specialty Pharmacy

Jan 25, 2022, 10:00 ET

Share this article

Share toX

Share this article

Share toX

ALTAMONTE SPRINGS, Fla., Jan.25, 2022 /PRNewswire-PRWeb/ --BioPlus Specialty Pharmacy, a CarepathRx company and the leading independent specialty pharmacy in the United States, today announced that capecitabine, a generic oncology medication, is ready to ship to patients within 24 hours of receiving a complete physician referral.

BioPlus is the only specialty pharmacy to guarantee that capecitabine is ready to ship in 24 hours. Until now, no other pharmacy has ever eliminated the excess waiting period — the time from diagnosis to starting therapy — that oncology patients have historically experienced when prescribed treatment.

"When patients have been diagnosed with cancer but have to wait long periods to begin treatment, their clinical outcomes and emotional burdens are impacted in ways that should be avoidable," explained Angie Houck, Senior Vice President of Sales Operations at BioPlus. "This is why our specialty pharmacy has invested in the systems and processes needed to have their capecitabine ready to ship in 24 hours. With our enhanced operational process, we reduce wait time and stress for patients and their providers."

Clinical Studies Show That Time Matters When Initiating Treatment
Numerous studies indicate that timely access to cancer treatment can make a significant difference for patients. Time to treatment initiation (meaning the length of time from diagnosis to first treatment) in patients newly diagnosed with cancer correlates with outcomes, in terms of both survival and quality of life.

"Time matters. When patients start their medications faster, it's possible to add precious time and quality to their lives," added Houck.

Delays in time to treatment initiation, according to an analysis of a large patient population tracked by the National Cancer Database, found that each additional week of time to treatment initiation is associated with an increase of mortality ranging from 1.2-3.2% per week for early-stage breast, lung, renal, and pancreatic cancers, and 0.5% per week for colorectal cancer.

Similarly, in other research, longer wait times to treatment initiation affected long-term survival for any cancer, as measured by 5-year and 10-year survival rates.

"BioPlus knows that timely care is critical, especially in oncology. Keeping things moving through the steps from diagnosis to prescription fulfillment is why we are committed to being faster than other pharmacies," said Mark Montgomery, CEO and President of BioPlus. "This is the heart of our 2 Hour, 2 Day, 2 Click promises. And, for capecitabine, think of it as hope delivered in 24 hours."

Fast Capecitabine Therapy Initiation Begins with the Power of 2
The oncology patient's medication journey begins with a long-standing program at BioPlus that serves all patients: the 2 Hour Patient Acceptance Guarantee™ ensuring notification to physician offices in less than two hours whether a referred patient is accepted for treatment or not.

BioPlus' patient financial assistance department helps ensure that financial issues don't delay or interrupt patient treatment. In addition, it takes patients with qualifying BioPlus prescriptions only two clicks to refill online.

When time matters, referring a capecitabine prescription to BioPlus means that patients' medications are guaranteed to be ready-to-ship within 24 hours of the pharmacy receiving the complete referral (excluding weekends).

About BioPlus Specialty Pharmacy

Meet the only independent, national specialty pharmacy to back up 'fast & easy' with the Power of 2. Part of the CarepathRx family of pharmacy and medication management solutions, BioPlus Specialty Pharmacy offers a 2 Hour Patient Acceptance Guarantee™ so physician offices quickly know whether a referred patient is accepted for treatment. Then prescriptions are on their way with our 2 Day Ready 2 Ship™. Medication refills are an easy 2 clicks away for qualifying prescriptions.  

Ranked #1 by both patients and prescribers, BioPlus provides a complete range of specialty pharmacy services for cancer, multiple sclerosis, hepatitis C, and other complex, chronic conditions. BioPlus also offers concierge-class infusion services and expertise.  

For every referral received, BioPlus provides a life-saving antibiotic through our partnership with OneWorld Health. It's part of our global vision to heal the world 2gether, helping to ensure patients across town and around the world have access to life-saving and life-sustaining medications.

Media Contact

Dr. Roxie Mooney, BioPlus Specialty Pharmacy, +1 4075753220, [email protected]

Twitter

SOURCE BioPlus Specialty Pharmacy

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.